Accelerating the transition from diagnosis to available treatments for rare metabolic and neurodegenerative diseases
CENTOGENE and Takeda extend their contract to continue providing access to genetic testing for patients with rare metabolic diseases and rare neurodegenerative diseases. The global market access and expansion partnership originally established in 2015 aims to provide efficient and timely diagnosis to patients. towards appropriate, readily available therapies that can improve their quality of life
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 28, 2022 (GLOBE NEWSWIRE) — Centogene NV (Nasdaq: CNTG), the essential commercial-stage life science biodata partner for rare and neurodegenerative diseases, today announced that it has extended its partnership with Takeda (TSE: 4502/NYSE: TAK) to diagnose patients with rare metabolic and neurodegenerative diseases.
Under this agreement, CENTOGENE will continue to provide Takeda with access to diagnostic testing for patients worldwide. The fee-for-service commercial agreement focuses on expanding patient access to diagnostics for lysosomal storage disorders such as Fabry and Gaucher disease and Hunter syndrome.
“We are excited to expand our partnership with Takeda to provide diagnostics and accelerate improved treatments and health outcomes for patients around the world,” said Kim Stratton, CEO of CENTOGENE. “With our highly differentiated diagnostic services, CENTOGENE’s network of more than 29,000 physicians, and the CENTOGENE biological database that generates new insights, we are uniquely positioned to add significant value to biopharmaceutical partners throughout of their development pipeline. This collaboration will support the expansion of Takeda’s world-class enzyme replacement therapies and, more importantly, bring real solutions to underserved patient communities.
As part of this partnership, CENTOGENE’s exclusive CentoCard® dried blood drop solution offers simple logistics for centralized diagnostic testing. One of the key assets of the partnership is the CENTOGENE Biodatabank, the world’s largest repository of real-world data on rare and neurodegenerative diseases, which is pioneering access to commercial multiomics products on the market today.
In January 2015, CENTOGENE initially entered into an agreement with Shire Pharmaceuticals, which was acquired in 2019 by Takeda, to provide diagnostic testing capability to improve early diagnosis of patients with rare genetic diseases. Last year, the contract was extended until March 2022.
CENTOGENE is committed to the diagnosis and research around rare diseases by transforming real-world clinical, genetic and multiomics data to diagnose, understand and treat rare diseases. Our goal is to bring rationality to treatment decisions and accelerate the development of new orphan drugs by using our deep knowledge and data on rare diseases. CENTOGENE has developed an exclusive global rare disease platform based on our real-world data repository of over 650,000 people representing over 120 different countries.
The Company’s platform includes epidemiological, phenotypic and genetic data that reflects a global population, as well as a biobank of patient blood samples and cell cultures. CENTOGENE believes it is the only platform focused on comprehensive multi-level data analysis to improve understanding of rare inherited diseases. It enables better identification and stratification of patients and their underlying diseases to enable and accelerate the discovery, development and access to orphan drugs. As of December 31, 2021, the Company collaborated with more than 30 pharmaceutical partners.
This press release contains “forward-looking statements” within the meaning of the United States federal securities laws. Statements contained herein that are not clearly historical in nature are forward-looking, and the words “anticipate”, “believe”, “continue”, “expect”, “estimate”, “intend to “, “to project”, and similar expressions and future or conditional verbs such as “will”, “would”, “should”, “might”, “could”, “may” and “can” are generally intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause the actual results, performance or achievements of CENTOGENE to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. . These risks and uncertainties include, among others, adverse economic and geopolitical conditions as well as instability and volatility in global financial markets, possible changes in current and proposed laws, regulations and government policies, pressures from increasing competition and consolidation in our industry, expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our dependence on third parties and partners collaboration, including our ability to manage growth and build new customer relationships, our reliance on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations in our results of operations due to the effect of changes, our ability to rationalize the use of cash, our need for additional financing or other factors. For more information about the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as the risks associated with CENTOGENE’s business generally, see CENTOGENE’s risk factors stated in CENTOGENE’s Form 20-F filed on March 30, 2022, with the Securities and Exchange Commission (the “SEC”) and subsequent filings with the SEC. All forward-looking statements contained in this press release speak only as of the date hereof, and CENTOGENE specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
CENTOGENE Lennart Streibel Investor Relations [email protected]